Merck gets PTAB to nix Pfizer vaccine patent

On Wednesday, 13 March 2019 the Patent Trial and Appeal Board (PTAB) invalidated every claim of a Pfizer patent tied to next generation pneumonia vaccines, handing a win to rival Merck Sharp & Dohme Corp., which persuaded the board to ax a patent for a different pneumonia vaccine last year.

In a series of four final written decisions in inter partes reviews addressing different claims and invalidity arguments about the patent, the board found that Merck had shown that all 45 claims are invalid as obvious. It also rejected Pfizer's motion to amend the claims.

Read More: Merck gets PTAB to nix Pfizer vaccine patent


Share Back To Listing
Loading data